Trade Desk (NASDAQ:TTD – Get Free Report) was downgraded by stock analysts at Evercore ISI from an “outperform” rating to an “inline” rating in a research note issued to investors on Thursday, ...
Teradata (NYSE:TDC – Free Report) had its target price cut by Evercore ISI from $37.00 to $32.00 in a research report report ...
Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning ...
Hosted on MSN13h
Evercore ISI Group Upgrades CRISPR Therapeutics (CRSP)Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As ...
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.
Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback